Erythropoietin Drug Market 2022-2028

Description

List of Tables

Global Erythropoietin Drug Market Size, Share & Trends Analysis Report by Product type (Epoetin Alfa, Epoetin Beta, Darbepoetin-Alfa, and Others), By Application (Hematology, Kidney Disorders, Cancer, and Others) Forecast 2022-2028

The global Erythropoietin Drug market is anticipated to grow at a CAGR of around 5.6% during the forecast period. It has been 15 years since the initial demonstration was done for erythropoietin for cancer. It was proved that this drug can reduce anemia which occurs due to cancer in the human body. Clinical trials since that time have proved an increase of hemoglobin in the human body. Improving hemoglobin levels with RCB is also an option but it proved to be risky and can increase toxic content in the human body. Epoetin Alfa, Epoetin Beta, and Darbepoetin-Alfa are not identical when the comparison is made with reference to structure and composition, all of them have different effects on survival. A major share of health care resources is invested in the use of erythropoietin drugs. Naturally, erythropoietin is produced to help as a regulator of RBC, and it controls the proliferation of immature erythroid progenitors from entering into mature red cells. For instance, in Feb 2022, Active biotech and Oncode institute in the Netherlands, have agreed to acquire global rights to patent, which will be of using tasquinimod and inhibitors of S100 for treatment in myelofibrosis. Myelofibrosis is a type of bone marrow cancer in which the normal production of blood cells is disturbed.

The global erythropoietin drug market is segmented based on Product type and application. Based on Product type, the market is segmented into epoetin alfa, epoetin beta, darbepoetin-alfa, and others. Based on the application, the market is sub-segmented into hematology, kidney disorders, cancer, and others. Among these, the use of erythropoietin drugs in kidney disorders expected to be more as compared to other disorders. For instance, in March 2022, GlaxoSmithKline Plc has announced that the European medicine agency(EMA) has granted a marketing authorization application to daprodustat. This drug will be used for the treatment of anemia due to chronic kidney disease. This drug was developed keeping in mind the unique Nobel prize-winning science.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific is going to be a good market for Erythropoietin drugs as people in these regions are affected by chronic diseases at a high rate than other parts of the world. Health institutions are working for betterment in these regions. For instance, in March 2022, Beijing Kaideni medical technology Co.Ltd. is a platform that works for the financing of chronic kidney disease. Financing is done by some known private investment institutions and medical enterprises.

The major companies serving the global Erythropoietin Drug market are Amgen Inc., Johnson & Johnson, Hospira Inc., F.Hoffman-La Roche AG, LG Chem, and others. The market players are working in a consistent way to provide their consumers with healthy and clean food and medicines. And for this, they are adopting different market strategies such as mergers and acquisitions, new product launches, business expansion, partnership collaboration, and others. For instance, in March 2022, US-based Thermo fisher calls for new proposals for its oncology clinical research. This will enhance more research profiling on cancer at the genomic level. Since the start of the program in 2020, Thermo fisher has awarded research grants to 16 projects worldwide for research in hematology-oncology.

Research Methodology

The market study of the global Erythropoietin Drug market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.
Whitepapers, research papers, and news blogs.
Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Erythropoietin Drug Market Research and Analysis by Product type.

2. Global Erythropoietin Drug Market Research and Analysis by Application.

The Report Covers:

Comprehensive Research Methodology of the global Erythropoietin Drug market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global Erythropoietin Drug Market.
Insights about market determinants that are stimulating the global Erythropoietin Drug market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: OMR2026324

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on The Global Erythropoietin Drug Market
Recovery Scenario of Global Erythropoietin Drug Market
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. BY Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Amgen Inc.
- 3.1.1. Overview
- 3.1.2. Financial Analysis
- 3.1.3. SWOT Analysis
- 3.1.4. Recent Developments
3.2. Johnson and Johnson
- 3.2.1. Overview
- 3.2.2. Financial Analysis
- 3.2.3. SWOT Analysis
- 3.2.4. Recent Developments
3.3. Hospira Inc.
- 3.3.1. Overview
- 3.3.2. Financial Analysis
- 3.3.3. SWOT Analysis
- 3.3.4. Recent Developments
3.4. F.Hoffman-La Roche AG
- 3.4.1. Overview
- 3.4.2. Financial Analysis
- 3.4.3. SWOT Analysis
- 3.4.4. Recent Developments
3.5. LG Chem.
- 3.5.1. Overview
- 3.5.2. Financial Analysis
- 3.5.3. SWOT Analysis
- 3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players

4. Market Segmentation

4.1. Global Erythropoietin Drug Market by Product type
- 4.1.1. Epoetin Alfa
- 4.1.2. Epoetin Beta
- 4.1.3. Darbepoetin Alfa
- 4.1.4. Others
4.2. Global Erythropoietin Drug Market by Application
- 4.2.1. Hematology
- 4.2.2. Kidney Disorders
- 4.2.3. Cancer
- 4.2.4. Others

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Biocon Ltd.
6.2. Celltrion Inc.
6.3. Dr. Reddy's Laboratories Ltd.
6.4. Emcure Pharmaceuticals
6.5. Intas Pharmaceuticals
6.6. Kirin Holdings Co.Ltd.
6.7. Novartis International AG
6.8. Pfizer Inc.
6.9. Ranbaxy Laboratories Ltd.
6.10. Sun Pharmaceuticals Industries Ltd.
6.11. Teva Pharmaceutical Industries Ltd.